Is the adefovir plus entecavir combination therapy superior than adefovir plus lamivudine in patients with antiviral resistant chronic hepatitis B?
의약학 > 내과학
( Yu Ri Cho ) , ( Dong Hyeon Lee ) , ( Jeong Hoon Lee ) , ( Su Jong Yu ) , ( Jung Hwan Yoon ) , ( Hyo Suk Lee ) , ( Yoon Jun Kim )
대한내과학회 추계학술발표논문집 2011년, 제2011권 제1호, 45(총1쪽)
42846240.pdf [무료 PDF 뷰어 다운로드]
  • ※ 본 자료는 참고용 논문으로 수정 및 텍스트 복사가 되지 않습니다.
  • 구매가격
    30원 (구매자료 3% 적립)
    이메일 발송  스크랩 하기
    자료 다운로드  네이버 로그인
    Background: Antiviral resistance is a major challenge for the treatments that are currently available for hepatitis B virus. However, the efficacy of adefovir (ADV) and entecavir (ETV) combination therapy in patients who developed antiviral resistance was not fully evaluated. In this study, we aimed to evaluate the efficacy of ADV and ETV combination therapy as compared to the efficacy of LAM and ADV in patients with antiviral resistant chronic hepatitis B (CHB). Methods: Antiviral resistance was defined as follows: persistently detectable HBV DNA after 36 weeks after LAM or ADV therapy ; virological breakthrough with previous LAM or ADV therapy ; or documented LAM or ADV-resistant mutations. We assessed 90 patients with antiviral resistant CHB. Of these, 27 patients were treated with a combination of ADV+ETV and 63 patients were treated with a combination of LAM+ADV. The virological and biochemical parameters were compared between the two groups at 3, 6, 9 and 12 months, respectively. Results: Treatment with a combination of ADV+ETV resulted significant difference in virological response compared to that in the LAM+ADV group through 12 months (p=0.001). At 12 months, the HBV DNA declined more in the ADV+ETV group than that in the LAM+ADV group (-4.52±1.956 vs. -2.65±1.723 log10IU/ml; p=0.001). The rate of a virological non-response, which is defined as <1 log10IU/ml reduction in HBV DNA concentration at 3 months was significantly greater in the LAM+ADV group than that in the ADV+ETV group (26.78% vs. 7.40%, p=0.022). Also, the rate of a virological complete response at 12 months was greater in the ADV+ETV group than that in the LAM+ADV group (73.68% vs. 31.48%, p=0.005). In the multivariate analysis, parameters related to a virological response at Month 12 were the baseline HBV DNA level [OR, 0.403 ; p=0.004] and virological non-response at Month 3 [OR, 0.102 ; p=0.028]. Conclusion: In patients with antiviral resistant CHB, the response to ADV+ETV was significantly superior compared to that of the LAM+ADV group for suppressing HBV DNA through 12 months. The result indicates that ADV+ETV should be used in the patients antiviral resistant CHB, especially in the area where tenofovir is not available.
    사업자등록번호 220-87-87785 대표.신현웅 주소.서울시 서초구 방배로10길 18, 402호 대표전화.070-8809-9397
    개인정보책임자.박정아 통신판매업신고번호 제2017-서울서초-1765호 이메일
    copyright (c) 2009 happynlife. steel All reserved.